Loading
Muscle Physiology and Disorders / CRISPR and Genetic Engineering · Journal article
Genome Medicine · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This proof-of-concept study demonstrates that CRISPR/Cas9-mediated insertion of deleted dystrophin exons can restore full-length dystrophin expression and rescue multiple in vitro cardiac phenotypes in patient-derived iPSCs carrying a two-exon deletion. The findings are mechanistic and preliminary; they establish technical feasibility but do not address efficacy, safety, or translatability to human disease.
Single-line proof-of-concept study using CRISPR/Cas9 genome editing and in vitro iPSC differentiation. Duchenne muscular dystrophy patient-derived iPSC line with deletion of exons 49–50; in vitro differentiation to cardiac cell types. Intervention: CRISPR/Cas9-mediated insertion of deleted exon 49–50 coding sequences at 3' of exon 48 to restore full-length dystrophin. Compared with: Isogenic corrected iPSCs versus unedited DMD iPSCs (implied but not explicitly stated as a separate arm).
Full-length dystrophin re-expressed in corrected cardiomyocytes via CRISPR/Cas9 insertion approach Edited cardiomyocytes showed improved morphology and reduced troponin I release (damage marker) Dystrophin restoration decreased ROS production and enhanced contractility with improved Ca2+ kinetics
In vitro surrogate endpoints only; no animal efficacy, safety, or toxicity data
This is a mechanistic, single-line study demonstrating technical proof-of-concept for CRISPR/Cas9 restoration of multi-exon dystrophin deletions in vitro. It does not yet support clinical translation and should be viewed as foundational work requiring validation in independent patient lines and animal models.
First-in-human demonstration of CRISPR/Cas9 correction of multi-exon DMD deletion in patient iPSCs with rescue of in vitro cardiac phenotypes, but limited to a single cell line, surrogate endpoints, and no animal or clinical translation yet.
As stated by the source record.
This is a mechanistic, single-line study demonstrating technical proof-of-concept for CRISPR/Cas9 restoration of multi-exon dystrophin deletions in vitro. It does not yet support clinical translation and should be viewed as foundational work requiring validation in independent patient lines and animal models.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Duchenne muscular dystrophy (DMD) is a X-linked disease affecting skeletal and cardiac muscle and is caused by mutations in the dystrophin gene ( DMD ). Patient-derived induced pluripotent stem cells (iPSCs) serve as reliable in vitro disease models. Their genetic correction by CRISPR/Cas9 allows the generation of isogenic controls and holds promises for gene therapy. However, restoring full-length dystrophin, especially when deletions involve multiple exons, constitutes a technological challenge. This study aimed to fully repair the dystrophin gene from a DMD iPSC line carrying the deletion of exons 49–50 and to characterize the rescue of the cardiac phenotype. We developed an innovative CRISPR/Cas9-based approach involving the insertion of coding sequences of the deleted region, at the 3’ of exon 48, thereby generating a single continuous coding sequence encompassing exons 48-49-50. Subsequently, iPSCs were differentiated into cardiomyocytes and cardiac fibroblasts. Cardiac phenotypes were analysed by western blot, immunofluorescence, ELISA, FACS, Ionoptix, 3D engineered heart tissue (EHT) and single-nuclei RNA-seq. The correction of a two-exons DMD gene deletion in Duchenne iPSCs, using CRISPR/Cas9, enabled the re-expression of a stable and functional full-length dystrophin in cardiomyocytes resulting in the rescue of cardiac pathological phenotypes. Edited cardiomyocytes showed improved morphology, reduced release of the cardiomyocytes damage marker troponin I, and decreased ROS production. Moreover, dystrophin restoration enhanced contractility and ameliorated the Ca 2+ kinetics. Notably, edited iPSC derived fibroblasts showed reduced pro-fibrotic stimuli response. In parallel, we also observed enhanced functioning of a 3D engineered heart tissue and profound change in the transcriptomic profile in both cardiomyocytes and fibroblasts after the re-expression of full-length dystrophin. We developed an innovative approach that enabled the re-expression of full-length dystrophin in a DMD iPSC line with consequent complete rescue of in vitro DMD cardiac phenotypes. On the long term, these results could lay a foundation for future applications of cell therapy or in vivo CRISPR/Cas9-based intervention to treat DMD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.